The U.S. Food and Drug Administration (FDA) issued a warning about a rare but highly disconcerting condition that may occur with the use of a class of type 2 diabetes medications called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,